Minimal Residual Disease (Mrd) in Early Stage Follicular Lymphoma Can Predict Prognosis and Drive Rituximab Treatment After Radiotherapy

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_87
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Novel Molecular Markers for Minimal Residual Disease (Mrd) Monitoring in Mantle Cell and Follicular Lymphoma: The Targeted Locus Amplification (Tla) NGS Strategy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Maintenance Rituximab or Observation After Frontline Treatment With Bendamustine-Rituximab for Follicular Lymphoma

British Journal of Haematology
Hematology
2018English

Do Cytogenetics Predict Likelihood to Attain Minimal Residual Disease (MRD) Post Autologous Stem Cell Transplantation (SCT) in Multiple Myeloma (MM)?

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Monitoring of Minimal Residual Disease (MRD) Is Useful to Predict Prognosis of Adult Patients With Ph-Negative ALL: Results of a Prospective Study (ALL MRD2002 Study)

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2010English

Preventing Relapse After Haematopoietic Stem Cell Transplantation for Acute Leukaemia: The Role of Post-Transplantation Minimal Residual Disease (MRD) Monitoring and MRD-directed Intervention

British Journal of Haematology
Hematology
2017English

A Clofarabine-Based Bridging Regimen in Patients With Relapsed ALL and Persistent Minimal Residual Disease (MRD)

Bone Marrow Transplantation
TransplantationHematology
2013English

Bone Marrow in Follicular Lymphoma Prognosis

Russian Journal of Biotherapy
2016English

OUTCOMES AFTER EARLY TRANSFORMATION (tPOD24) VS. EARLY FOLLICULAR LYMPHOMA PROGRESSION (fPOD24) IN FOLLICULAR LYMPHOMA TREATED WITH FRONTLINE IMMUNOCHEMOTHERAPY

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy